RecruitingNot ApplicableNCT07177482

ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients

Sponsor

Deling Li

Enrollment

20 participants

Start Date

Jul 4, 2025

Study Type

INTERVENTIONAL

Conditions

Craniopharyngioma

Summary

This study aims to investigate 68Ga-MY6349, an immune-PET tracer targeting trophoblast cell surface antigen 2 (Trop2), for the noninvasive diagnosis of craniopharyngioma in vivo.

Eligibility

Min Age: 14 YearsMax Age: 80 Years

Inclusion Criteria3

must be able to provide a written informed consent
radiologically presumed and/or histologically confirmed craniopharyngioma scheduled for resection
adequate clinical condition (Karnofsky performance status ≥70)

Exclusion Criteria5

concomitant major central nervous system disorders
severe hepatic or renal dysfunction
history of severe allergy or hypersensitivity to intravenous radiographic contrast agents
claustrophobia precluding PET/CT or MRI examinations
pregnancy or breastfeeding

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TEST68Ga-MY6349 PET/CT

Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET/CT imaging within the specified time.

Locations(1)

Beijing Tiantan Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07177482

Related Trials

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

NCT0546517420 locations

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

NCT062998912 locations